Previous close | 35.40 |
Open | 35.40 |
Bid | 35.95 |
Ask | 37.65 |
Strike | 100.00 |
Expiry date | 2026-06-18 |
Day's range | 35.40 - 35.40 |
Contract range | N/A |
Volume | |
Open interest | 85 |
The Committee for Medicinal Products for Human Use recommends marketing authorization for Moderna's updated mRNA COVID-19 jab, Spikevax.
Despite becoming one a household name during the pandemic, Moderna stock has mostly fallen over the past three years amid slow sales.
The FDA authorization for NVAX's updated COVID-19 vaccine makes it the only non-mRNA vaccine option in the country.